Start here if you're new
what it is
Compass Pathways is testing a psilocybin treatment for depression and PTSD.
how it gets paid
Last year Compass Pathways made n/a in revenue.
what just happened
EPS came in at -$2.09, and Compass still has no reported revenue in the supplied filing data.
At a glance
B balance sheet — gets the job done, barely
80/100 earnings predictability — you can trust these numbers
-$2.30 fy2024 eps est
1.55 beta
~$725M market cap
xvary composite: 57/100 — below average
What they do
Compass Pathways is testing a psilocybin treatment for depression and PTSD.
The moat is the FDA process, not a moat. You are backing 1 lead drug and a long approval path, with 166 employees doing the work. That is a lab with a stock ticker, not a drug empire.
How they make money
n/a
annual revenue
The products that matter
pre-revenue depression drug program
psilocybin treatment program
zero revenue · Phase 3 is the catalyst
this is effectively the whole company today: no sales yet, estimated EPS of -$2.30, and a $725M market cap resting on one late-stage clinical thesis.
binary outcome
clinical development platform
regulatory and trial execution
B balance sheet · $21M debt
for a company with no revenue, execution is the product. the B balance sheet and just $21M of long-term debt give management time, but not endless time.
time matters
Key numbers
$725M
Market cap
The market is paying $725M for a company with $0M trailing revenue. That is a pure approval bet.
$2.30
2024 EPS est.
expects a -$2.30 loss per share in 2024. On a $7.02 stock, that is a third of the price.
1.55
Beta
A 1.55 beta means the stock has moved 55% more than the market. Your ride is rougher than average.
$21M
Long-term debt
Long-term debt is $21M, or 3% of capital. Debt is not the main fight here.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $21M (3% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CMPS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
EPS came in at -$2.09, and Compass still has no reported revenue in the supplied filing data.
The latest quarter showed a -$2.09 EPS loss, which was 45% worse vs. prior year. Revenue and gross margin were not provided in the source data, so the loss is the only hard earnings number here.
$0M
revenue
$2.09
eps
n/a
n/a
the number that mattered
The -$2.09 EPS loss matters because it says Compass is still spending more than it brings in.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Phase 3 failure for its psilocybin depression program.
med
the entire equity story depends on one late-stage readout
CMPS has zero revenue today. if Phase 3 disappoints, there is no operating business on this page to fall back on.
impact: a failed or messy trial would hit the reason investors are here in the first place.
med
losses are real even if debt is low
estimated EPS is -$2.30 and revenue is still n/a. the company only has so many ways to fund development before dilution becomes part of the story.
impact: low debt helps, but pre-revenue biotech investors usually get diluted before they get paid.
med
approval is not the same thing as a business model
even a successful trial only gets CMPS to the next hard part: regulation, reimbursement, and building a treatment workflow around a novel therapy.
impact: a drug can work clinically and still take longer than investors want to become meaningful revenue.
all of the current $725M valuation rests on a company with no revenue, estimated EPS of -$2.30, and one thesis that still needs to clear Phase 3.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
Phase 3 timing is the entire calendar
for CMPS, the next meaningful milestone is trial progress. with zero revenue today, the calendar matters more than quarterly sales.
metric
watch the loss line, not the p/e
estimated EPS is -$2.30 and trailing p/e is n/a. in human terms: profitability tools do not help much until the company becomes commercial.
trend
volatility is not a side effect here
a 1.55 beta and 5 / 100 price stability tell you the stock already trades like a high-risk clinical asset.
risk
cash runway matters more than debt ratios
long-term debt is only $21M, but a pre-revenue biotech can still pressure shareholders if development runs longer than expected.
Analyst rankings
earnings predictability
80 / 100
the reported numbers have been relatively steady. in human-speak, analysts can model the losses more easily than they can model the breakthrough.
risk profile
2
this system flags it as safer than 80% of stocks on balance-sheet factors. that does not mean the clinical thesis is safe. it means the capital structure is not the main problem.
source: institutional data
Institutional activity
institutional ownership data for CMPS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive